7,854 Shares in Astrazeneca Plc $AZN Acquired by Hamel Associates Inc.

Hamel Associates Inc. purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, Holdings Channel.com reports. The firm purchased 7,854 shares of the company’s stock, valued at approximately $1,378,000.

Several other large investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new stake in shares of Astrazeneca during the 3rd quarter worth approximately $25,000. Bangor Savings Bank boosted its position in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca during the 4th quarter worth approximately $30,000. YANKCOM Partnership acquired a new stake in shares of Astrazeneca during the 4th quarter worth approximately $31,000. Finally, TFC Financial Management Inc. boosted its position in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after acquiring an additional 335 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the subject of several research reports. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Tuesday. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Astrazeneca in a research note on Monday. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Price Performance

AZN stock opened at $178.87 on Thursday. The company has a fifty day moving average price of $190.12 and a 200-day moving average price of $185.76. The company has a market capitalization of $277.42 billion, a P/E ratio of 26.86, a PEG ratio of 1.60 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts expect that Astrazeneca Plc will post 9.37 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.